Skip to main content
Top
Published in: BMC Infectious Diseases 1/2018

Open Access 01-12-2018 | Research article

Whole blood profiling of leprosy type 1(reversal) reactions highlights prominence of innate immune response genes

Authors: Jamile Leão Rêgo, Nadja de Lima Santana, Paulo Roberto Lima Machado, Marcelo Ribeiro-Alves, Thiago Gomes de Toledo-Pinto, Léa Cristina Castellucci, Milton Ozório Moraes

Published in: BMC Infectious Diseases | Issue 1/2018

Login to get access

Abstract

Background

The major factors contributing for nerve damage and permanent disabilities in leprosy are type 1 or reversal reactions (RR) and type 2 or erythema nodosum leprosum (ENL). Gene profiling of leprosy reactions have shown that different pathways are activated during the course of reactions, which is consistent with the exacerbated immune response exhibited by these patients.

Methods

We used qPCR to screen a panel of 90 genes related to the immune response in leprosy in RNA-derived peripheral leukocytes of patients with (N = 94) and without leprosy reactions (N = 57) in order to define expression signatures correlated to RR or ENL.

Results

Our results show that there is a marked signature for RR in the blood, comprising genes mostly related to the innate immune responses, including type I IFN components, autophagy, parkins and Toll like receptors. On the other hand, only Parkin was differentially expressed in the ENL group.

Conclusions

The data put together corroborates previous work that brings evidence that an acute uncontrolled exacerbated immune response designed to contain the spread of M. leprae antigens might be cause of RR pathogenesis. Identifying a blood profile useful to predict leprosy reactions prior to its development might help to reduce the morbidity associated to this disabling disease.
Literature
1.
go back to reference Agrawal A, et al. Neurological manifestations of Hansen's disease and their management. Clin Neurol Neurosurg. 2005;107(6):445–54.CrossRefPubMed Agrawal A, et al. Neurological manifestations of Hansen's disease and their management. Clin Neurol Neurosurg. 2005;107(6):445–54.CrossRefPubMed
2.
go back to reference Eichelmann K., G.G.S., Salas-Alanis JC, Ocampo-Candiani J., Leprosy An update: definition, pathogenesis, classification, diagnosis, and treatment. Actas Dermo-Sifiliográficas, 2013. 104(7): p. 554–563. Eichelmann K., G.G.S., Salas-Alanis JC, Ocampo-Candiani J., Leprosy An update: definition, pathogenesis, classification, diagnosis, and treatment. Actas Dermo-Sifiliográficas, 2013. 104(7): p. 554–563.
3.
go back to reference Lastória JC, de Abreu MAMM. Leprosy: review of the epidemiological, clinical, and etiopathogenic aspects - part 1. An Bras Dermatol. 2014;89(2):205–18.CrossRefPubMedPubMedCentral Lastória JC, de Abreu MAMM. Leprosy: review of the epidemiological, clinical, and etiopathogenic aspects - part 1. An Bras Dermatol. 2014;89(2):205–18.CrossRefPubMedPubMedCentral
4.
go back to reference Rêgo JL, et al. The role of ERBB2 gene polymorphisms in leprosy susceptibility. Braz J Infect Dis. 2015;19:206–8.CrossRefPubMed Rêgo JL, et al. The role of ERBB2 gene polymorphisms in leprosy susceptibility. Braz J Infect Dis. 2015;19:206–8.CrossRefPubMed
5.
go back to reference Geluk A, et al. Longitudinal immune responses and gene expression profiles in type 1 leprosy reactions. J Clin Immunol. 2014;34(2):245–55.CrossRefPubMed Geluk A, et al. Longitudinal immune responses and gene expression profiles in type 1 leprosy reactions. J Clin Immunol. 2014;34(2):245–55.CrossRefPubMed
6.
go back to reference Dupnik KM, et al. Transcriptional changes that characterize the immune reactions of leprosy. J Infect Dis. 2015;211(10):1658–76.CrossRefPubMed Dupnik KM, et al. Transcriptional changes that characterize the immune reactions of leprosy. J Infect Dis. 2015;211(10):1658–76.CrossRefPubMed
7.
go back to reference Moraes MO, et al. Anti-inflammatory drugs block cytokine mRNA accumulation in the skin and improve the clinical condition of reactional leprosy patients. J Investig Dermatol. 2000;115(6):935–41.CrossRefPubMed Moraes MO, et al. Anti-inflammatory drugs block cytokine mRNA accumulation in the skin and improve the clinical condition of reactional leprosy patients. J Investig Dermatol. 2000;115(6):935–41.CrossRefPubMed
9.
go back to reference Ridley D, Jopling W. Classification of leprosy according to immunity. A five-group system. Int J Lepr Other Mycobact Dis. 1966;34(3):255–73.PubMed Ridley D, Jopling W. Classification of leprosy according to immunity. A five-group system. Int J Lepr Other Mycobact Dis. 1966;34(3):255–73.PubMed
10.
go back to reference WHO, Action Programme for the Elimination of Leprosy. Efficacy of single dose multi drug therapy for the treatment of single-lesion paucibacillary leprosy. Geneva : World Health Organization, 1997. 69(2): p. 121–129. WHO, Action Programme for the Elimination of Leprosy. Efficacy of single dose multi drug therapy for the treatment of single-lesion paucibacillary leprosy. Geneva : World Health Organization, 1997. 69(2): p. 121–129.
12.
14.
go back to reference de Toledo-Pinto TG, et al. STING-dependent 2′-5′ Oligoadenylate Synthetase–like production is required for intracellular Mycobacterium leprae survival. J Infect Dis. 2016;214(2):311–20.CrossRefPubMed de Toledo-Pinto TG, et al. STING-dependent 2′-5′ Oligoadenylate Synthetase–like production is required for intracellular Mycobacterium leprae survival. J Infect Dis. 2016;214(2):311–20.CrossRefPubMed
15.
go back to reference Cambier CJ, et al. Phenolic glycolipid facilitates mycobacterial escape from Microbicidal tissue-resident macrophages. Immunity. 2017;47(3):552–565.e4.CrossRefPubMedPubMedCentral Cambier CJ, et al. Phenolic glycolipid facilitates mycobacterial escape from Microbicidal tissue-resident macrophages. Immunity. 2017;47(3):552–565.e4.CrossRefPubMedPubMedCentral
16.
go back to reference Tracy OC, Lubor B, Mathias H. CCL2-CCR2 signaling in disease pathogenesis. Endocrine, Metabolic & Immune Disorders - Drug Targets. 2015;15(2):105–18.CrossRef Tracy OC, Lubor B, Mathias H. CCL2-CCR2 signaling in disease pathogenesis. Endocrine, Metabolic & Immune Disorders - Drug Targets. 2015;15(2):105–18.CrossRef
17.
go back to reference Gosling J, et al. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest. 1999;103(6):773–8.CrossRefPubMedPubMedCentral Gosling J, et al. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest. 1999;103(6):773–8.CrossRefPubMedPubMedCentral
18.
go back to reference Behfar S, et al. A brief look at the role of monocyte chemoattractant protein-1 (CCL2) in the pathophysiology of psoriasis. Cytokine. 2017 Behfar S, et al. A brief look at the role of monocyte chemoattractant protein-1 (CCL2) in the pathophysiology of psoriasis. Cytokine. 2017
19.
go back to reference Mendonça VA, et al. Immunology of leprosy. An Bras Dermatol. 2008;83(4):343–50.CrossRef Mendonça VA, et al. Immunology of leprosy. An Bras Dermatol. 2008;83(4):343–50.CrossRef
Metadata
Title
Whole blood profiling of leprosy type 1(reversal) reactions highlights prominence of innate immune response genes
Authors
Jamile Leão Rêgo
Nadja de Lima Santana
Paulo Roberto Lima Machado
Marcelo Ribeiro-Alves
Thiago Gomes de Toledo-Pinto
Léa Cristina Castellucci
Milton Ozório Moraes
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2018
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-018-3348-6

Other articles of this Issue 1/2018

BMC Infectious Diseases 1/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.